Full Name
Dr. Nina Wressnigg
Hospital/Organisation/Company
CEPI
Speaker Bio
Dr. Nina Wressnigg joined the Coalition for Epidemic Preparedness Innovations (CEPI) as Head of Clinical Development Science in March 2023.
Nina is an infectious disease vaccinologist with extensive expertise in clinical strategy developing vaccines from preclinical to late-stage development. She conducted her PhD at the Mount Sinai School of Medicine (MSSM), New York, U.S, developing live-attenuated influenza vaccine candidates by reverse genetics and obtained her PhD in microbiology and genetics from the University of Vienna, Austria.
Nina spend more than 15 years in various preclinical and clinical development roles of increasing responsibility in vaccine industry. From 2016 to 2022, during her last appointment as Director Clinical Strategy at Valneva, Austria, she was responsible for progressing the Chikungunya vaccine from preclinical stage to late-stage clinical development. In addition, she worked on early-stage Zika vaccine candidate development and scientific engagement for Valneva’s inactivated COVID vaccine.
Her prior research at Baxter International Inc. (now Takeda) from 2010 to 2015 involved the clinical development and life-cycle management of vaccines for several infectious diseases at various stages of development including Chikungunya (Phase 1), Zika (Phase 1), Ross-River (Phase 3), Tickborne Encephalitis (Phase 4), seasonal and pandemic Influenza (Phase 3), Meningococcal C (Phase 4) as well as Lyme Borreliosis (Phase 3-ready). Following her PhD, Nina worked in pre-clinical development at the biotechnology start-up, AVIR Greenhills Biotechnology, Austria, conducting research on live-attenuated influenza vaccine candidates.
Nina is an infectious disease vaccinologist with extensive expertise in clinical strategy developing vaccines from preclinical to late-stage development. She conducted her PhD at the Mount Sinai School of Medicine (MSSM), New York, U.S, developing live-attenuated influenza vaccine candidates by reverse genetics and obtained her PhD in microbiology and genetics from the University of Vienna, Austria.
Nina spend more than 15 years in various preclinical and clinical development roles of increasing responsibility in vaccine industry. From 2016 to 2022, during her last appointment as Director Clinical Strategy at Valneva, Austria, she was responsible for progressing the Chikungunya vaccine from preclinical stage to late-stage clinical development. In addition, she worked on early-stage Zika vaccine candidate development and scientific engagement for Valneva’s inactivated COVID vaccine.
Her prior research at Baxter International Inc. (now Takeda) from 2010 to 2015 involved the clinical development and life-cycle management of vaccines for several infectious diseases at various stages of development including Chikungunya (Phase 1), Zika (Phase 1), Ross-River (Phase 3), Tickborne Encephalitis (Phase 4), seasonal and pandemic Influenza (Phase 3), Meningococcal C (Phase 4) as well as Lyme Borreliosis (Phase 3-ready). Following her PhD, Nina worked in pre-clinical development at the biotechnology start-up, AVIR Greenhills Biotechnology, Austria, conducting research on live-attenuated influenza vaccine candidates.
